Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ovarian cancer.
Hennessy BT, Coleman RL, Markman M. Hennessy BT, et al. Among authors: markman m. Lancet. 2009 Oct 17;374(9698):1371-82. doi: 10.1016/S0140-6736(09)61338-6. Epub 2009 Sep 28. Lancet. 2009. PMID: 19793610
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr. Fu S, et al. Among authors: markman m. Cancer. 2011 Apr 15;117(8):1661-9. doi: 10.1002/cncr.25701. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472713 Free PMC article. Clinical Trial.
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB. Fu S, et al. Among authors: markman m. Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6. Gynecol Oncol. 2012. PMID: 22487539 Free PMC article. Clinical Trial.
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Hennessy BT, et al. Among authors: markman m. J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606085 Free PMC article.
Emerging therapeutics for primary peritoneal cancer.
Slomovitz BM, Worley MJ, Markman M, Coleman RL. Slomovitz BM, et al. Among authors: markman m. Expert Opin Emerg Drugs. 2011 Mar;16(1):71-84. doi: 10.1517/14728214.2011.526600. Expert Opin Emerg Drugs. 2011. PMID: 21352070 Review.
Optimal management of recurrent ovarian cancer.
Markman M. Markman M. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S40-3. doi: 10.1111/IGC.0b013e3181bf8143. Int J Gynecol Cancer. 2009. PMID: 19955913 Review.
815 results